Cream for external treatment of graham-little-piccardi-lasseur syndrome

FIELD: chemistry.

SUBSTANCE: invention discloses a cream for external treatment of Graham-Little-Piccardi-Lasseur syndrome, which contains lanolin, peach oil and distilled water, and is characterised by that it further contains chloroquine, wherein components of the cream are in a defined ratio given in g%.

EFFECT: inhibiting progression of scarring without marked side effects.

 

The invention relates to medicine, in particular to the field of dermatology and cosmetology, and can be used for the external treatment of the syndrome Piccardi-Graham-little-Glassware. The invention consists in that the claimed non-steroidal outer medicinal product in cream form contains chloroquine, lanolin, peach oil, distilled water in the following ratio of components:

Chloroquine 1-1,5 g%

Lanolin 33-35 g%

Oil peach 33-35 g%

Distilled water 20-28,5 g%.

Famous cream (for therapeutic and prophylactic treatment of skin diseases) "Dermovate", contains: clobetasol propionate, propylene glycol, sorbitan sesquioleate, white soft paraffin, distilled water (Boichenko A.A. Scar and naruszenie alopecia: classification, etiology, pathogenesis, clinical picture and treatment. // Ukr. dermatology and cosmetology. - 1998. No. 2. - S. 45-54; Mashkovsky PPM Medicines. In 2 volumes, 14th ed. - M.: OOO "New Wave", Publisher Sbelow, 2002. 1. - 544 S.; T. 2. -608 C.).

Famous cream (for the correction of skin diseases) "Cold-cream", which contains: lanolin 30 g%peach oil 30 g%, distilled water 30 g% and which is used in the treatment of skin diseases (Dermatology: a textbook for medical schools / Avemco, VBR the ins. - SPB.: Spec lit, 2008, at 352 S.).

The lack of Dermovate is its high cost, and the presence he has significant side effects when applied externally, such as skin atrophy, scarring, steroid dependence, the effect of the cancellation. The application of this cream in the syndrome Piccardi-Graham-little-Glassware does not meet the treatment needs of this study, as it can lead to further scarring due to side effects.

The disadvantage of Cold-cream is that it does not contain the necessary active ingredients for the prevention and treatment of scarring when the syndrome Piccardi-Graham-little-Glassware.

The purpose of the invention is to develop an economically acceptable composition of non-steroidal cream, which has curative properties for external correction syndrome Piccardi-Graham-little-Glassware quickly and inhibiting the progression of scarring, with no side effects.

The objective is achieved by the fact that persons suffering from syndrome Piccardi-Graham-little-Glassware, when treatment is prescribed a cream containing chloroquine 1-1,5 g%, lanolin 33-35 g%, oil of peach 33-35 g%, distilled water 20-28,5 g%.

Cream prescribed topically twice daily to the lesions, thin layer, within two months of therapy.

The cream is used following the way. Persons suffering from syndrome Piccardi-Graham-little-Glassware, appointed as external therapy cream containing chloroquine 1-1,5 g%, lanolin 33-35 g%, oil of peach 33-35 g%, distilled water 20-28,5 g%. The cream is prescribed externally in the form of lubricating twice daily to the lesions, within two months of therapy.

Chloroquine - white or white with a light white crystalline powder, bitter taste. Easily soluble in water, very little alcohol.

Well and rapidly absorbed in the gastrointestinal tract, the maximum concentration (Cmax) is 2 to 6 h; partially biotransformation and slowly excreted from the body (half-life period (T1/2) - 30-60 day). Used in the treatment of skin diseases. Range of action of chloroquine is directed to the inhibition of nucleic acid synthesis, reduces the activity of certain enzymes, slows immunological processes.

Chloroquine is widely used in the treatment of collagenoses such as systemic lupus erythematosus, scleroderma, and especially rheumatoid arthritis (in the latter case, it is considered as one of the basic products).

I believe that the basis of therapeutic effect of chloroquine is immune effect, the predominant influence on the metabolism of immune cells, and connective tissue (Mashkovsky, M. D. medical environments is TBA. In 2 volumes, 14th ed. - M.: OOO "New Wave", Publisher Sbelow, 2002. - T. 1. - 544 S.; T. 2. - 608 S.).

The results of our research show about the effectiveness of chloroquine immunological skin diseases, leading to associated with scarring, in particular. the syndrome Piccardi-Graham-little-Glassware. Chloroquine add in the cream composition is used for treatment of these diseases.

To prove the achievement of the purpose of the invention us at the clinic of skin and venereal diseases, Military Medical Academy clinical studies were conducted to assess the impact of effectiveness of the proposed cream for the treatment of syndrome Piccardi-Graham-little-Glassware (Boichenko A.A. Scar and naruszenie alopecia: pathogenesis and therapy: Dis.... Kida. the honey. Sciences. - SPb. Military medical Academy, 1999. - 255 HP; Males A.V., Boichenko A.A. Dermatohistopathology changes syndrome, Piccardi-Graham-little-Glassware. // Actual problems of dermatology, Mycology and sexually transmitted infections. - Blagoveshchensk: ASMA, 2000. - S. 120-121; Males A.V., Boichenko A.A. Syndrome Piccardi-Graham-little-Glassware: histopathological studies. // Native dermatovenerology-2000: problems, research and solutions: Sat. the scientific. Tr. - Nizhny Novgorod: Publishing house of the Volga-Vyatka Academy of gosslugbi 2000. - S. 11-12; Males A.V., Barinov CENTURIES, ALEXANDER Sukharev, Boichenko A.A. Syndrome Piccardi-Graham-little-Glassware: dermatohistopathology and local immunological changes. // Actual problems of dermatology: Ubil. collection of scientific. Tr.- Vol. II.- Kursk, 1999. - S. 82-83; Males A.V., Boichenko A.A. Syndrome Piccardi-Graham-little-Glassware: a comprehensive clinical, dermatohistopathology, immunological and endocrinological research. // Vestnik St.Petersburg University. Dermatol. and venerol. - 2001. No. 6. - S. 4-11; Boichenko A.A., Macronectes O.N., Alpatov NR. Changes in some biochemical parameters in the peripheral blood of patients with syndrome Piccardi-Graham-little-Glassware. // Young scientists and professionals health care of St. Petersburg in the XXI century. - SPb., Military medical Academy, 2000. - S. 15-16; Sukharev AV, Boichenko A.A., Alpatov, VN, Macronectes O.N. Some features of endocrine status in patients with syndrome Glassware-little. // V all-Russian scientific-[. "Current issues of diagnosis and treatment in a multidisciplinary health care institution", 26-27 April 2001.- SPb.: BI, 2001. - S. 140).

The object of the study were people with syndrome Piccardi-Graham-little-Glassware.

There were formed four groups of subjects: three groups of observations and a control group. The group was formed from among persons suffering from syndrome Piccardi-Graham-little-is Issuer, and voluntarily agreed to participate in the study. The size of each group was 20 people, which was sufficient to obtain representative of the findings of the research.

External treatment of the first group was the cream "Dermovate", the outer second first treatment group was "Cold-cream, external treatment of the third group was the cream containing chloroquine, lanolin, peach oil, distilled water in the following ratio of components: chloroquine 1-1,5 g%, lanolin 33-35 g%, oil of peach 33-35 g%, distilled water 20-28,5 g%, individuals in the control group received a topical treatment with placebo.

Study of the effective use of creams was based on clinical data, biochemical, endocrinological studies, histological and immunohistochemical studies of skin biopsies (Boichenko A.A. Some features of common and external therapy of patients with chronic inflammatory dermatoses with irreversible defeat balances-hair of the apparatus. // Young scientists and professionals health care of St. Petersburg in the XXI century. - SPb., Military medical Academy, 2000. - S. 16-17.; Boichenko A.A. Experience total and external therapy of patients with chronic inflammatory dermatoses with irreversible defeat balances-hair so is she. // V all-Russian scientific-practical use. proc. "Current issues of diagnosis and treatment in a multidisciplinary health care institution", 26-27 April 2001. - SPb.: BI, 2001. - S. 33; Boichenko A.A. Chronic inflammatory dermatosis with irreversible defeat balances-hair system: experience in complex dermatological therapy. // Herald Of The Russian Military the honey. Acad. - 2009. No. 1 (25), Etc., O'clock P. - S. 638; Boichenko A.A. Chronic inflammatory dermatosis with irreversible defeat balances-hair machine: our experience of modern complex dermatological therapy. // Third Russian).[. "St. Petersburg dermatological read, September 17-18, 2009: abstracts. Conf., SPb.: "Man and his health". - P.10-11; Boichenko A.A. Experience of modern complex dermatological therapy of chronic inflammatory dermatosis with irreversible defeat balances-hair of the apparatus. // IV Russian).practical use. proc. "St. Petersburg dermatological read", October 21-22, 2010: abstracts. Conf., SPb.: "Man and his health". - S. 25-26.).

All patients in addition to examination, collection of medical history and history of life, clinical, serological, immunological, biochemical, endocrinological analyses of blood, coagulation, light microscopy hair and remote studies of the scalp in the rays of the lamp wood brass who was born diagnostic biopsy of the skin of the scalp with subsequent histological examination, and immunophenotyping of cell subpopulations in cryostatic sections. If you have the appropriate complaints and abnormalities in blood and urine of patients were conducted additional research to identify foci of chronic infection and endocrine diseases, including orthopantomography, x-rays of the sinuses of the nose, x-rays of the Turkish saddle, ultrasound examination of thyroid gland, organs of abdominal cavity and small pelvis, advice maxillofacial surgeon and doctor, ENT specialist, and consulting a gynecologist, endocrinologist, neurologist and psychiatrist (with the written consent of the patient).

Diagnostic excisional [Raznatovic IM et al., 1995] deep [Cockerell .J., 1994; Pinkus H. et al., 1981] biopsy of skin of the scalp was performed by the method of Goldstein, L.M. et al.(1987). Fence biopsy was performed on the boundary of the most recent [Cockerell .J., 1994] focus baldness. Histological examination was carried out using the method of staining with hematoxylin and eosin, eosin-Gram method according to Weigert, azocarmine method Mallory in the modification of HEIDENHAIN, method, Masson, method Hale, as well as CHIC-reaction [Lewer W.F., 1958; Pearse, A. G. E., 1962]. During histological examination according to the method of Raznatovic IM et al.(1995) using a light microscope EU-SANCTUARY R-13 (the OMO, Russia) studied at least two drugs of the scalp, obtained from each patient, and each drug was studied at least five vertical slices [Baden N. R., 1987].

Determination of subpopulations of T - and b-lymphocytes in cryostatic sections of the biopsies was performed indirect immunofluorescence method using monoclonal antibodies (MCAT) receptor CDla, CD3, CD4, CD8, CD 14, CD16, CD20 (DAKO, Denmark), and deposits of immunoglobulins a, M and G is a direct immunofluorescence method using monospecific antisera to these immunoglobulins ("Sevac, Czech Republic). Microscopic examination of the obtained preparations we were counting labeled cells or deposits of immunoglobulins in fluorescent microscope LUMAM FROM (LOMO, Russia) with increasing H and water immersion. For each item, MCAT or monospecific antisera examined not less than 3 slices in 9 fields of view in each, with drew attention to the location of labeled cells in the epidermis, the dermis, in the follicular epithelium); the results were processed by semi-quantitative method: the absence of cells, labeled MCAT corresponded to 0 points, from 1 to 5 cells in field of view - 1 point, from 6 to 15 cells in the field of view is 2 points, from 16 to 25 cells per field of view is 3 points, from 26 cells 4 points.

To assess the efficacy of treatment, in addition to JV the social methods of clinical examination, we used the following semi-quantitative methods:

1) a sample Zalkind E. C. (1959);

2) counting the number of hair [J. Gray et al., 1999], remaining on the pillow after a night's sleep, on the ridge after the first day of TouchUp on the grid - after taking a shower with washing the head;

3) noted the start time of hair growth;

4) count the number of growing hair in the lesions on the area of 9 cm and their characteristics (tiny, gray, long, pigmented long).

The effect of treatment was assessed on a scale of:

1) improved (1 point) - sample Zalkind E. C. negative; the results of tension tests of hair and counting the number of hair significantly different from those before therapy; in patients with syndrome Piccardi-Graham-little-Glassware managed to get the machine to stop scarring;

2) no effect (0 points) - changes in the clinical picture of the disease is not observed;

3) deterioration (-1 point) - noted negative changes in the clinical picture and results of special tests (see above).

The results were statistically processed using the following types of statistical analysis:

1) calculation of numerical characteristics of random variables according to the results of observations;

2) assess the accuracy and reliability of the average value of a random variable;

3) determination from sidelnyk values of the frequency according to the results of a sample survey;

4) evaluation of the accuracy and reliability of the relative magnitudes of frequencies;

5) testing of statistical hypotheses from the results of sample observations by parametric t-test (t) and Fisher (F)and non-parametric criterion of Pearson (χ2), the criterion of inversions Mann-Whitney (U), criterion ranks of the Kruskal-Wallis (H), the criterion of Wilcoxon rank (T) and the test series of Wald-Wolfowitz (S);

6) correlation analysis using parametric coefficient of pair correlation Pearson (rHu), and nonparametric - correlation coefficient of Candala (τ) and rank correlation coefficient (coefficient of Association) Spearman (ρ);

7) multivariate analysis of variance for Latin square scheme of the second order.

Research results:

At follow-up examination of patients with syndrome Piccardi-Graham-little-Glassware 2 months after the start of treatment it was found that the effectiveness of the above methods of external therapy proved equal using the proposed non-steroidal anti-inflammatory cream to 0.97±0,12 [points], when using "Dermovate" - 0,62±0,18 [points], when using Cold-cream - 0,20±0,37 [points], in the control group (placebo) - -0,5+0,5 [points].

Thus, the efficiency of the offered cream is 0.97±0,12 [the point is] or 97%, and statistically significantly differed upwards when using Cold-cream (S=11; p<0.05), and Dermovate" (S=15; p<0.05) in the comparison group, and this was significantly higher than placebo in the control group (S=9; p<0,05).

The proposed formulation of the cream helps to reduce the activity of the immunopathological process in the scalp of patients, which contributes to the prevention of scarring in the skin in patients with syndrome Piccardi-Graham-Glassware-little.

Naturally, our proposed and studied a cream containing chloroquine 1-1,5 g%, lanolin 33-35 g%, oil of peach 33-35 g%, distilled water 20-28,5 g%, cannot and should not completely replace complex dermatological therapy of patients with syndrome (regimen, diet, General therapy, topical therapy, physical therapies). The main purpose of its application is the maximum possible correction of various disorders of the immune processes in the skin of the scalp that occurs when the syndrome Piccardi-Graham-Glassware-little. This cream has a therapeutic and prophylactic effect on foci of scarring, primarily due to its non-steroid immunosuppressive actions.

Cream for topical treatment of syndrome Piccardi-Graham-little-Glassware, including lanolin, oil peach, distillers is nnow water, characterized in that it additionally contains chloroquine, in the following ratio of components:
Chloroquine 1-1,5 g%
Lanolin 33-35 g%
Oil peach 33-35 g%
Distilled water 20-28,5 g%



 

Same patents:

FIELD: chemistry.

SUBSTANCE: invention relates to compounds of general formula or , where Ar1 represents phenyl group, optionally substituted with one or several identical or non-identical halogen atoms; R1 represents hydrogen atom; R4, R5, R6a, R6b represent hydrogen atoms; Y, Z independently represent linear C1-4 alkylene group, optionally substituted with one linear C1-4 alkyl group; Ar2 stands for condensed with benzene 5-membered heterocyclic ring, containing one nitrogen atom and one sulphur atom, substituted with one linear C1-4 alkyl group, or derivative of 5- or 6-membered heterocyclic ring, containing one nitrogen atom and one sulphur atom, condensed with heteroaromatic 6-memebered ring, containing one or two nitrogen atoms, substituted with one linear C1-4 alkyl group, linear C1-4 alkoxygroup or group -NR7R8, where R7 and R8 independently stand for hydrogen atom, linear or branched C1-4 alkyl group, or R7 and R8 together with nitrogen atom form group of general formula , where R2, R3 represent linear C1-4 alkyl groups, A stands for group -CHR12, oxygen atom or group -NR9, where R12 and R9 stand for hydrogen atom or linear C1-4 alkyl group, m has value 1 or 2, n has value 1 or 2, o has value 0 or 1, p has value 0 or 1, Q stands for group -O-, group -N--H or group -N--CO-R10, where R10 stands for linear C1-4 alkyl group or -NH-R11 group, where R11 represents linear C1-4 alkyl group; and to their salts. Invention also relates to methods of obtaining therein and to based on them pharmaceutical composition, possessing antagonistic activity with respect to receptor CCR3.

EFFECT: obtained are novel compounds and based on them pharmaceutical compositions, which can be applied in medicine for obtaining medication, intended for treating asthma, allergic rhinitis, atopic dermatitis, eczema, inflammatory intestinal diseases, ulcerous colitis, Crohn's disease, allergic conjunctivitis, multiple sclerosis or HIV-infection and AIDS-associated diseases.

14 cl, 3 tbl, 26 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: what is presented is using 10-[(3R)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10H-phenothiazine, 10-[(3S)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10H-phenothiazine or 10-[(3R,3S)-1 -azabicyclo[2.2.2]oct-3-ylmethyl]-10H-phenothiazine or its pharmaceutically acceptable salts for preparing a drug for preventing or treating obstructive bronchopneumopathy characterised by the fact that the drug is presented in the oral form providing an administered dose of 1 mcg/kg to 10 mg/kg, and characterised by the fact that the drug is presented in the form of a solution for oral pulverisation or a powder for inhalation.

EFFECT: invention provides the respiration recovery, specifically respiration rate, and increases an inspiration and expiration flow, reduces an infiltrated neutrophil count and a direct anti-inflammatory effect.

4 cl, 2 dwg, 10 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, namely to an agent for treating an oral mucosal involvement accompanying lichen acuminatus. An adhesive ointment for treating the oral mucosal involvements accompanying lichen acuminatus containing sea buckthorn oil and 0.5% prednisolone ointment, socoseryl dental adhesive paste and vitamin A in the specific proportions.

EFFECT: ointment is effective for treating the oral mucosal involvements accompanying lichen acuminatus.

3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, particularly dermatology, namely to a film coating solution for the removal of pathological nail keratoderma, containing: 10 to 20% of urea, 8 to 12% of the film coating polymer Eudragit E100, 45 to 50% of ethanol, 1 to 5% of propylene glycol, 0.5 to 1% of diethylphthalate, and water up to 100%.

EFFECT: invention provides preparing a transparent film coating high-urea solution.

5 cl, 4 ex

FIELD: medicine.

SUBSTANCE: invention refers to cosmetic and pharmaceutical industry and represents a method for improving the transdermal permeability of therapeutic or cosmetic topical preparations involving the dermal administration of 1.0 to 300.0 vol. % of liquid xenon as a part of an acceptable neutral carrier or a therapeutic or cosmetic preparation.

EFFECT: invention provides the higher therapeutic or cosmetic effectiveness ensured by improving the transdermal transport of bioactive compounds.

8 cl, 13 ex, 4 dwg

FIELD: medicine.

SUBSTANCE: there are presented: a method of treating a disorder associated with the exposure to an alkylating agent specified in a group: sulphur mustard, nitrogen mustard, chlorine gas, 2-chlor-ethylethylsulphide and phosgene gas by introducing an effective amount of tetrakis-N,N-diethylimidazolium porphyrine or a pharmaceutically acceptable salt, particularly AEOL-10150, and a respective method for protection of an individual against toxic effects related to the exposure to the above alkylating agents. The porphirin AEOL-10150 analogue, a free radical acceptor MnTbap keeps the cell viability unchanged in the similar environment.

EFFECT: what is shown is achieving the declared applications: prevention of the organ disorders, and organ recovery following the exposure to sulphur mustard.

15 cl, 15 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, namely to pharmacy and concerns the development of an ointment containing mechanically activated amorphous or amorphous crystalline calcium gluconate, and may be used in the integrated treatment of skin diseases related to calcium deficiency, namely to the integrated treatment of dermatoses: psoriasis, atopic dermatitis, eczema and keratoderma. As an active ingredient, the ointment contains mechanically activated amorphous or amorphous crystalline calcium gluconate; an ointment base is Vaseline, glycerol, emulsifier No.1, Lutrol F 127 and purified water in the following proportions, wt %: mechanically activated amorphous or amorphous crystalline calcium gluconate-5.0; Vaselin-10.0; glycerol-10.0; emulsifier No.1-8.0; lutrol F 127-2.0 and purified water up to 100.0.

EFFECT: ointment possesses high therapeutic activity, provides the uniform release of the active ingredient that is mechanically activated amorphous or amorphous crystalline calcium gluconate, the manifested prolonged action and applicability by the patient.

4 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of medicine, namely to obstetrics and gynecology, and can be applied for prevention of antenatal infection of fetus by herpes simplex virus. For this purpose local and system episodic treatment with Acyclovir is carried out in case of herpetic infection relapse. In addition, antihomotoxic therapy is carried out by medicine Engistol for three months at pregravidal stage in women infected by virus herpes simplex. Dose of intake for the first month is 1 pill 3 times per day, for the second month - 1 pill 2 times per day, third month - 1 pill 1 time per day; and in the period of gestation in form of tree courses of antihomotoxic therapy by medication Engistol in dose 1 pill 3 times per day in terms 14-18 weeks, 24-28 weeks, 34-38 weeks of pregnancy.

EFFECT: method is non-invasive, safe for the health of pregnant woman and fetus, available for institution of obstetrics, increases efficiency of prevention of antenatal fetus infection.

FIELD: chemistry.

SUBSTANCE: invention relates to sulphonamide compounds of formula or pharmaceutically acceptable salts thereof, wherein A is phenyl, optionally substituted with 1 or 2 halogen atoms, C1-6 alkyl group, trifluoromethyl group, C1-6 alkoxy group or -SCH3 group, thiophenyl, optionally substituted with a C1-C6 alkyl group or a halogen atom, pyridinyl, optionally substituted with a halogen atom, naphthalenyl or dihydroindenyl; R1 denotes the following formulae or [in formulae (R1a) and (R1b) Ar1 denotes the following formulae , or (each R5 and R6 independently denotes a hydrogen atom, a halogen atom, a C1-6 alkyl group optionally substituted with up to three halogen atoms, C1-6 lower alkoxy group optionally substituted with up to three halogen atoms); Ar2 denotes the following formulae , or (each R7 and R8 independently denotes a hydrogen atom, a hydroxyl group, a halogen atom, a C1-6 alkyl group optionally substituted with up to three halogen atoms or a C1-6 lower alkoxy group optionally substituted with up to three halogen atoms, an amine group, a nitro group, a C2-6 acyl group, or R7 and R8 together form -CH2CH2O-; R9 is a hydrogen atom or - J-COOR10; J is a covalent bond, alkylene containing 1 to 5 carbon atoms, alkenylene containing 2 to 5 carbon atoms or alkynylene containing 2 to 5 carbon atoms, where one carbon atom in said alkylene groups can be substituted with an oxygen atom, a sulphur atom, NR11, CONR11 or NR11CO in any chemically acceptable position; R11 is a hydrogen atom; and R10 is a hydrogen atom); and p equals 0 or 1]; R2 is a C1-6 alkyl group; each R3 and R4 is independently a C1-6 alkyl group; * denotes an asymmetric carbon atom; and m equals an integer from 1 to 3. The invention also relates to a medicinal agent for stimulating PTH secretion.

EFFECT: obtaining novel compounds which can be used in medicine to prevent or treat primary or secondary osteoporosis.

29 cl, 15 tbl, 14 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: what is presented is using a composition containing galactooligosaccharide, fructooligosaccharide and uronic acid oligosaccharide in preparing a composition for oral administration into an infant for preventing the local administration of corticosteroids and/or preventing the administration of a calcineurin inhibitor into the above infant, wherein uronic acid oligosaccharide represents a pectin degradation product and/or an alginate degradation product, and wherein using the corticosteroids and/or administering the calcineurin inhibitor is applicable for treating eczema, infantile eczema, atopic dermatitis, dermatitis herpetiformis, contact dermatitis, seborrheic dermatitis, neurodermatitis, psoriasis and intertrigo. Particularly, the composition is a nutritional composition.

EFFECT: what is shown is reducing probability of the local administration of corticosteroids and dermatological preparations to be required for the purpose of preventing the above skin diseases, or reducing the length of using the corticosteroids.

5 cl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to the field of cosmetology, namely to a cosmetic composition for peroral introduction, which contains a combination of lycopene, vitamin C, vitamin E and at least one polyphenol compound, obtained from pine bark, in which the ratio of weight content of polyphenol compound to the sum of weight contents of lycopene, vitamin C and vitamin E constitutes from 0.3 to 0.7, as s single active ingredient.

EFFECT: invention is intended for prevention and/or treatment of wrinkles in the area of eyes and mouth angles, small wrinkles, eye bags and dark circles under eyes.

22 cl, 2 ex, 11 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: there are presented: using nalbuphine salt in the form of a hydrophilic emulsion suppository for treating moderate to severe pain syndrome, a pharmaceutical composition for the same application in the form of suppositories comprising nalbuphine hydrochloride as an active substance and a hydrophilic emulsion base in the following ratio, g/100 g of the composition: nalbuphine hydrochloride 0.0125-5.00, hydrophilic emulsion base up to 100 g, and a method for preparing the same.

EFFECT: effective and prolonged analgesic action with no laxative action has been shown.

7 cl, 3 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to biotechnology and immunology. What is presented is a method for preparing a vaccine with using reverse latex. The first stage involves preparing an adjuvant composition by dispersion of reverse latex or polymer powder prepared by reverse latex spraying, in a physiologically acceptable solution. The second stage involves mixing the prepared adjuvant composition with an antigen-containing medium for preparing the vaccine composition.

EFFECT: reverse latex adjuvant is characterised by higher safety and possesses the high adjuvant effect both at the level of the humoral response, and at the level of the cell response.

8 cl, 2 dwg, 3 ex

Topical composition // 2497516

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to a topical pharmaceutical composition in the form of an opaque emulsion gel. The composition contains 1.2-4 wt % of diclofenac diethylammonium salt, saturated or unsaturated C10-C18fatty alcohol, at least 40 wt % of water, C2-C4alkanol, glycol solvent, gelling agent, liquid lipid forming an oil phase of the emulsion gel, non-ionic surfactant and agent with the primary properties to reduce pH of the prepared composition to 6-9.

EFFECT: compositions under the invention are characterised by high skin permeability, extremely low systemic absorption, absence of human skin irritation after application, high chemical and physical stability, complete solubility of the active component and considerable relief of pain intensity.

8 cl, 4 tbl, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to chemical-pharmaceutical industry and represents a pharmaceutical composition for treating or preventing AIDS in an orally acceptable presentation containing: 1 to 99 wt % of at least one zeolite, montmorillonite or a mixture thereof as the ingredient F; 1 to 99 wt % of at least raw or dried blue-green algae as the ingredient G; 0 to 50 wt % of conventional pharmaceutical excipients and additives as the ingredient H; the total amount of the ingredients F, G and optionally H makes 100 wt %, with the weight ratio of the ingredients F and G at a dry basis falls within the range of 0.2:1 to 5:1.

EFFECT: invention provides creating a composition for treating or preventing AIDS containing a combination of zeolites and algae drugs.

11 cl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to pharmaceutical formulations and methods for preparing them of lipids for ophthalmological application containing a phospholipid ingredient containing natural zwitterion phospholipids, and an oil ingredient containing natural oil-in-water emulsions. The oil ingredient and phospholipid ingredient are preferentially related as 3:1; the phospholipid ingredient is found in the amount of 0.1%-5%, and the oil ingredient is found in the amount of 0.3%-15%.

EFFECT: group of inventions provides ocular drug delivery applicable for treating dry eye syndrome; it has an ability to recover the lipid lachrymal film layer, inhibits the inflammatory element observed.

37 cl, 19 tbl, 4 ex, 7 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a nanoemulsion as a carrier of a biologically active substance representing a DSIP or a herbal extract. The nanoemulsion contains water, a surfactant representing an ethylene oxide/ propylene oxide block copolymer, and a biopolymer in the form of mixed polysaccharide (PS) and polyaminosaccharide (PAS). The polysaccharide is 2-diethylaminoethyl-dextran or 3-dimethylaminopropyl-dextran. The polyaminosaccharide is chitosan or a chitosan derivative prepared by exhaustive alkylation of primary amino groups by glycidyl trimethylammonium chloride. The mass content of each of the polymers (ethylene oxide/ propylene oxide block copolymer, PS and PAS) in the mixture of polymers and nanoemulsion is found within the range of 0.1 to 0.7, while the ethylene oxide/ propylene oxide block copolymer concentration makes 0.4-4.0 g/l.

EFFECT: invention provides preparing the biologically compatible and storage-stable nanoemulsion.

2 cl, 7 ex

Nanoemulsion // 2491917

FIELD: medicine.

SUBSTANCE: group of inventions refers to a nanoemulsion for active agent delivery, a method for preparing it, compositions containing it, and to using a nanoemulsion for preparing pharmaceutical compositions for local application and cosmetic compositions for skin application. The declared nanoemulstion contains a water ingredient and a carrier which contains a lipophilic ingredient in the amount of 0.1-15 wt %, a surfactant and isopropyl and/or 1-propyl alcohol. The average emulsified particle diameter makes less than 100 nm. The method for preparing the nanoemulsion involves mixing the water ingredient and carrier containing the lipophilic ingredient, surfactant and isopropyl and/or 1-propyl alcohol, for preparing the nanoemulsion at temperature 50-60°C. The invention also refers to the composition for photodynamic therapy containing the above nanoemulsion and the active agent representing 5-aminolevulinic acid, a derivative, a precursor and/or a metabolite thereof. The above composition is applied to prepare the drug substance for photodynamic therapy and to treat senile keratosis. What is also declared is a diagnostic composition for detecting the dividing cells which contains the nanoemulsion and 5-aminolevulinic acid. The invention also refers to a kit for photodynamic therapy which comprises the composition for photodynamic therapy and one ingredient specified in a photoresist coating, an agent for attaching the above coating or an agent for applying the composition.

EFFECT: invention provides better stability and intensified cell and tissue penetration of the nanoemulsion.

25 cl, 6 dwg, 9 tbl, 5 ex

FIELD: chemistry.

SUBSTANCE: group of inventions relates to field of biochemistry. Claimed is preparation for preservation of culture of stem and differentiated human and animal cells in cultivation, storage and cryoconservation. Preparation represents gel, which contains emulsion of perfluororganic compounds (PFOC) in their stabilisation in emulsified state with water solution of non-ionogenic surface active compounds (SAS) based on block-copolymer of polyethylene oxide (PEO) and polypropylene oxide (PPO) with ratio PEO/PPO from 9:1 to 7:3. SAS concentration in preparation constitutes from 20 to 90% with average molecular weight of SAS from 5000 Da to 21000 Da. Content of PFOC in emulsion constitutes from 5 to 70 vol.%. Size of PFOC emulsion particles lies in the interval from 15 nm to 2000 nm. Water phase of gel contains osmolytes of organic and/or inorganic nature for supporting in it osmotic pressure from 250 to 350 mOsm. As PFOC emulsion, emulsion of perfluorodecalin, perfluoro methylcyclohexyl piperidine and perfluorotributylamine mixture can be used. Also claimed is method of obtaining said preparation. Extrusion of coarse mixture of water SAS solution and liquid PFOCs or PFOC mixture is performed under pressure 400-700 atm until emulsion is obtained. After that, it is mixed in hot condition with concentrated water solution of inorganic salts or osmolytes are added into it until osmotic pressure equal from 250 to 350 mOsm is obtained. Then obtained composition is cooled. After that, partial freeze-drying or centrifugation of gel with observation of temperature gradient and acceleration from 15000 g to 35000 g is performed. Methods of preservation of culture of stem and differentiated human and animal cells in storage, cryoconservation and cultivation are claimed. In storage of cells preparation with PFOC content from 15 to 59 vol.% is added to culture medium with controlled value pH=7.0-7.4, temperature 37°C in CO2 incubator atmosphere or with low pH<6.0, temperature 20°C in air atmosphere. In cryoconservation resuspended in fresh culture medium cells are placed into medium, which contains preparation with PFOC content 59-70 vol.%. After that, cooling is carried out in two stages: first at rate 1 degree per min to -80°C, then with maximally possibly rate to temperature -196°C. In cultivation of cells as medium component preparation with PFOC content from 15 to 70 vol.% is used.

EFFECT: cell cultures after cryoconservation, storage or cultivation in presence of PFOC-containing gels have on average 90% of viable cells, are easily separated from gel, re-inoculated in standard conditions, divided and fully preserve their functions and ability to differentiate.

16 cl, 23 dwg, 1 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine and pharmaceutical industry, particularly to creating a pharmaceutical composition of a submicron emulsion for parenteral administration, having anticonvulsant activity. The composition contains 5-carbamoyl-5H-dibenz-(b,f)-azepine, and additionally it contains soya been oil and sodium deoxycholate in the following proportions, wt %: 5-carbamoyl-5H-dibenz-(b,f)-azepine - 18.5-23.2, soya been oil - 2.1-2.3, sodium deoxycholate - 74.5-79.4. The composition has an average size of the deagglomerated microparticles of 108-132 nm.

EFFECT: composition enables the intravenous intraperitoneal administration of a low therapeutic dose with a high efficacy of the preparation, and reduction of dose-dependent adverse reactions, and extends the range of such preparations.

4 ex, 3 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: there are presented: using nalbuphine salt in the form of a hydrophilic emulsion suppository for treating moderate to severe pain syndrome, a pharmaceutical composition for the same application in the form of suppositories comprising nalbuphine hydrochloride as an active substance and a hydrophilic emulsion base in the following ratio, g/100 g of the composition: nalbuphine hydrochloride 0.0125-5.00, hydrophilic emulsion base up to 100 g, and a method for preparing the same.

EFFECT: effective and prolonged analgesic action with no laxative action has been shown.

7 cl, 3 tbl, 3 ex

Up!